Financhill
Back

Brainstorm Cell Therapeutics Quote, Financials, Valuation and Earnings

Invest in the Next Big AI Disruptor Today

Learn More
Sell
8

BCLI
Brainstorm Cell Therapeutics

Last Price:
2.23
Seasonality Move:
-7.58%

7 Day Trial

ALL ACCESS PASS

$ 7

AI Tech Innovator Poised for Strategic Buyouts Invest Now

Learn More

Brainstorm Cell Therapeutics Price Quote

$2.23
-0.11 (-15.53%)
(Updated: October 5, 2024 at 6:18 AM ET)

Brainstorm Cell Therapeutics Key Stats

Sell
8
Brainstorm Cell Therapeutics (BCLI) is a Sell

Day range:
$2.22 - $2.54
52-week range:
$2.01 - $11.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0%

Volume:
82.5K
Avg. volume:
28.5K
1-year change:
-17.73%
Market cap:
$12.5M
Revenue:
$0
EPS:
$-3.45

How Much Does Brainstorm Cell Therapeutics Make?

Data Unavailable

Is Brainstorm Cell Therapeutics Growing As A Company?

Data Unavailable

Brainstorm Cell Therapeutics Stock Price Performance

What Is Brainstorm Cell Therapeutics 52-Week High & Low?

Brainstorm Cell Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Brainstorm Cell Therapeutics?

Is Brainstorm Cell Therapeutics Cash Flow Positive?

Brainstorm Cell Therapeutics Return On Invested Capital

Data Unavailable

Brainstorm Cell Therapeutics Earnings Date & Stock Price

Brainstorm Cell Therapeutics Competitors

Brainstorm Cell Therapeutics Dividend Yield

Brainstorm Cell Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -33.33%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 51.85
Upside from Last Price: 2111.28%

Major Shareholders

  • How many BCLI shares are owned by institutional investors?
    14.2M BCLI shares are owned by institutional investors
  • How many BCLI shares are owned by insiders?
    4.1M BCLI shares are owned by insiders